0001209191-12-021639.txt : 20120403 0001209191-12-021639.hdr.sgml : 20120403 20120403203455 ACCESSION NUMBER: 0001209191-12-021639 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120330 FILED AS OF DATE: 20120403 DATE AS OF CHANGE: 20120403 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SHEMA SUZANNE M CENTRAL INDEX KEY: 0001225509 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-28298 FILM NUMBER: 12739966 MAIL ADDRESS: STREET 1: C/O ZYMOGENETICS, INC. STREET 2: 1201 EASTLAKE AVENUE CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ONYX PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001012140 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943154463 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 249 E. GRAND AVE. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-266-0000 MAIL ADDRESS: STREET 1: 249 E. GRAND AVE. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0305 4 2012-03-30 0 0001012140 ONYX PHARMACEUTICALS INC ONXX 0001225509 SHEMA SUZANNE M C/O ONYX PHARMACEUTICALS, INC. 249 EAST GRAND AVE. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 SVP, General Counsel Common Stock 2012-03-30 4 A 0 7500 0.00 A 37751 D Common Stock 2012-03-30 4 A 0 17150 0.00 A 54901 D Common Stock 2012-04-02 4 D 0 568 36.5777 D 54333 D Common Stock 2012-04-02 4 D 0 694 36.5781 D 53639 D Stock Option (Right to Buy) 37.68 2012-03-30 4 A 0 38200 0.00 A 2022-03-30 Common Stock 38200 38200 D Stock Option (Right to Buy) 37.68 2012-03-30 4 A 0 28000 0.00 A 2022-03-30 Common Stock 28000 28000 D Represents a restricted stock unit granted to the reporting person. The restricted stock unit vests annually over 3 years. Represents restricted stock units granted to the reporting person. Each restricted stock unit represents a right to receive one share of the issuer's common stock. The restricted stock unit vests upon the meeting of certain milestones. Payment of exercise price or tax liability by delivering or withholding securities incident to receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. Shares sold pursuant to a 10b5-1 plan. 12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months. The shares vest monthly from the date of grant at a rate of 1/48th per month over a period of 48 months. Suzanne Shema by /s/ Warren De Souza, Attorney-in-Fact 2012-04-03